SCHEMBL20819792

SCHEMBL20819792

C[C@H](c1cccc2ccccc12)N1C=CN([C@H](C)c2cccc3ccccc23)P1Br

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
ADRA2A P08913 4/20 0.38
ADRA2B P18089 4/20 0.38
ADRA2C P18825 4/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1B P35368 1/20 0.38
HSD11B1 P28845 2/20 0.38
NPBWR1 P48145 1/20 0.38
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
TSHR P16473 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22342839 1.00 CYP2C9 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL20826420 0.84 ACHE (0.36) CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL22319459 0.83 CYP2C9 (0.43) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL22342337 0.77 HSD11B1 (0.39) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL22342844 0.77 TSHR (0.38) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL22342841 0.72 ALDH1A1 (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL12846189 0.72 ALDH1A1 (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL22342843 0.71 ALDH1A1 (0.44) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL22319458 0.71 ALDH1A1 (0.44) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A
SCHEMBL20560402 0.70 ALDH1A1 (0.61) CYP2C9CYP2C19ALDH1A1CYP1A2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161863-B2 Chiral catalyst and method for asymmetric reduction of an imine DALHOUSIE UNIVERSITY (CA) 2021-11-02 US disclosed
US-20200255463-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE DALHOUSIE UNIVERSITY (CA) 2020-08-13 US disclosed
WO-2019051585-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE DALHOUSIE UNIVERSITY (CA) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255463-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE C1R, C5, C1S CYP2C9 43/4885CYP2C19 65/4885ALDH1A1 381/4885
US-11161863-B2 Chiral catalyst and method for asymmetric reduction of an imine C1R, C5, C1S CYP2C9 43/4885CYP2C19 65/4885ALDH1A1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.